Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Health consequences of androgenic anabolic steroid use

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Mossman-Pacey Paradox

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Response to letter: Observational studies investigating hip fracture risk: a fundamental methodological issue?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Male fertility before and after androgen abuse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Systemisk toksicitet ved lokalanalgetika

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Tidligt skift fra intravenøs fra intravenøs til antibiotikabehandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: The lifetime prevalence of androgenic anabolic steroid abuse is estimated to be around 6% for men, but there is limited knowledge about the side effects of these drugs. Objective: To investigate mortality and morbidity amongst users of androgenic anabolic steroids (AAS). Methods: In this retrospective matched cohort study, 545 male subjects tested positive for AAS in Danish fitness centres during the period 3 January 2006 to 1 March 2018. Subjects were matched with 5450 male controls. In addition, 644 men who were sanctioned because they refused to submit to a doping test and 6440 controls were included as a replication cohort. Results: Mortality was three times higher amongst users of AAS than amongst nonuser controls (hazard ratio 3.0, 95% CI 1.3–7.0). The median annual number of hospital contacts was 0.81 in the cohort of AAS users and 0.36 in the control cohort (P < 0.0001). Acne, gynaecomastia and erectile dysfunction affected more than 10% of the androgenic anabolic steroid users, and the prevalence of these disorders was significantly higher than in the control group (P < 0.0001). The results could be replicated in a similar cohort. Conclusion: Androgenic anabolic steroid users have an increased risk of dying and significantly more hospital admissions than their nonuser peers. Side effects of AAS and their metabolites were highly prevalent. Given the high rate of androgenic anabolic steroid abuse, these side effects are of public health concern.

OriginalsprogEngelsk
TidsskriftJournal of Internal Medicine
Vol/bind285
Udgave nummer3
Sider (fra-til)333-340
Antal sider8
ISSN0954-6820
DOI
StatusUdgivet - mar. 2019

ID: 55740060